MedTrace Logo

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

NCT01246986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2021-01-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

LY2157299

Administered orally

DRUG

Sorafenib

Administered orally

DRUG

Ramucirumab

Administered IV

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-30
Primary Completion
2019-06-06
Completion
2019-12-24

Countries

  • United States
  • Australia
  • France
  • Germany
  • Italy
  • New Zealand
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246986 on ClinicalTrials.gov